Autochthonous and dormant Cryptococcus gattii infections in Europe. by Hagen, F. et al.






The following full text is a publisher's version.
 
 





Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
Until recently, Cryptococcus gattii infections occurred 
mainly in tropical and subtropical climate zones. However, 
during the past decade, C. gattii infections in humans and 
animals in Europe have increased. To determine whether the 
infections in Europe were acquired from an autochthonous 
source or associated with travel, we used multilocus 
sequence typing to compare 100 isolates from Europe (57 
from 40 human patients, 22 from the environment, and 21 
from animals) with 191 isolates from around the world. Of 
the 57 human patient isolates, 47 (83%) were obtained since 
1995. Among the 40 patients, 24 (60%) probably acquired 
the C. gattii infection outside Europe; the remaining 16 
(40%) probably acquired the infection within Europe. Human 
patient isolates from Mediterranean Europe clustered into a 
distinct genotype with animal and environmental isolates. 
These results indicate that reactivation of dormant C. gattii 
infections can occur many years after the infectious agent 
was acquired elsewhere.
During the past decade, the basidiomycetous yeast Cryptococcus gattii has stepped out of the shadows of 
its sibling C. neoformans. The latter species mainly infects 
immunocompromised persons, and C. gattii mainly infects 
apparently immunocompetent persons. C. neoformans is 
found globally, and C. gattii has been mostly limited to 
tropical and subtropical areas in Central Africa, northern 
Australia, and Central and South America (1). However, 
this distribution pattern changed after an unprecedented 
outbreak of C. gattii emerged in the temperate climate of 
British Columbia, Canada, and expanded to the Pacifi c 
Northwest region of Canada and the United States (1,2). 
Epidemiologic studies have shown that C. gattii occurs 
in areas other than tropical or subtropical zones, such as 
in Mediterranean Europe, northern Europe, and western 
Australia (3–5).
For the purpose of studying the epidemiology of C. 
gattii, a broad variety of molecular biological techniques 
have been developed, including PCR fi ngerprinting, 
restriction fragment length polymorphism analysis of 
the PLB1 and URA5 loci, amplifi ed fragment length 
polymorphism (AFLP) fi ngerprint analysis, and several 
multilocus sequence typing (MLST) approaches (6–9). 
These laboratory investigations have shown that C. gattii 
can be divided into 5 distinct genotypes: AFLP4/VGI, 
AFLP5/VGIII, AFLP6/VGII, AFLP7/VGIV, and AFLP10/
VGIV (8,9). Serotype B strains occur in genotypes AFLP4/
VGI, AFLP6/VGII, and AFLP10/VGIV; serotype C strains 
are restricted to genotypes AFLP5/VGIII and AFLP7/
VGIV (8).
Recently, a consensus MLST scheme was proposed for 
epidemiologic investigations of C. gattii and C. neoformans, 
specifi cally, the nuclear loci CAP59, GPD1, IGS1, LAC1, 
PLB1, SOD1, and URA5 (9). So far, this consensus MLST 
scheme has been used to study the population structure of 
C. neoformans strains from Thailand and C. gattii strains 
from Australia (3,10).
We investigated the occurrence of C. gattii in Europe, 
focusing on whether this pathogen is emerging and, if so, 
how to explain this emergence pattern. Furthermore, we 
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Cryptococcus gattii in Europe
explored whether the infections originated from Europe 
or were introduced from other continents. To achieve 
these goals, members of the European Confederation of 
Medical Mycology were asked to send recently obtained 
human patient isolates of the species for detailed AFLP 
and MLST analyses. Thus, the genetic diversity of the 
yeast was used to trace its geographic origin to identify 
where the infections were acquired. AFLP genotyping 
results were combined with published C. gattii MLST 
results from Byrnes et al. (11) and Fraser et al. (12), which 
were extended to match the Cryptococcus consensus 
MLST scheme (9). Our study produced the following 5 
conclusions: all hitherto known genotypes of C. gattii 
are emerging in Europe; genotype AFLP4/VGI isolates 
predominate; a C. gattii cluster, which is endemic to 
Mediterranean Europe and genetically distinct from the 
other populations, exists; several human infections are 
caused by travel-related acquisition of C. gattii outside 
Europe; and autochthonous cases occur in Europe.
Materials and Methods
Strains and Media
We compared a collection of 107 isolates collected 
from Europe with 194 isolates collected globally (Table 1; 
online Technical Appendix Table 1, wwwnc.cdc.gov/EID/
pdfs/12-0068-Techapp.pdf). All isolates were checked for 
purity and cultivated on malt extract agar medium (Oxoid, 
Basingstoke, UK). Cultures were incubated for 2 days at 
30°C. A working collection was made by growing C. gattii 
strains on malt extract agar slants for 2 days at 30°C, after 
which the strains were stored at 4°C. Strains were stored 
long term at −80°C by using the Microbank system (Pro-
Lab Diagnostics, Richmond Hill, Ontario, Canada). 
Amplifi cation and Sequencing of MLST Loci
Genomic DNA extraction, AFLP genotyping, and 
mating-type determination by amplifi cation of either the 
STE12a or STE12α locus were performed as described (8). 
The 7 nuclear consensus MLST loci (CAP59, GPD1, IGS1, 
LAC1, PLB1, SOD1, and URA5) were amplifi ed by using the 
preferred primer combinations (9). To compare the current 
set of C. gattii strains with those from a published C. gattii 
population biology study, we included the 3 nuclear loci 
that are not part of the consensus MLST scheme (CAP10, 
MPD1, and TEF1α) (12). We also included isolates from 
a global study by Byrnes et al. (11) and Fraser et al. (12) 
and subjected them to amplifi cation and sequencing of the 
CAP59, SOD1, and URA5 loci.
Amplifi cations were conducted in a 25-μL PCR 
mixture containing 37.5 mmol/L MgCl2 (Bioline, London, 
UK), 1× PCR buffer (Bioline), 1.9 mmol/L dNTPs 
(Bioline), 0.5 U Taq DNA polymerase (Bioline), 5 pmol 
of both primers (Biolegio, Nijmegen, the Netherlands) 
(online Technical Appendix Table 2), and ≈100 ng of 
genomic DNA. PCRs were conducted with an initial 
denaturation step at 94°C for 5 min, followed by 35 
cycles of denaturation at 94°C for 30s, annealing for 30s 
(see Technical Appendix Table 2 for optimal annealing 
temperatures), extension at 72°C for 1 min, followed by 
72°C for 5 min and a fi nal dwell at 21°C.
Sequencing reactions were conducted with the BigDye 
version 3.1 chemistry kit (Applied Biosystems, Foster City, 
CA, USA) as described (13). For all amplifi cation products 
except CAP59, the initial amplifi cation primers were used 
for sequencing reactions. For CAP59, the newly designed 
forward primer CAP59L-Fwd and the original reverse 
primer JOHE15438 (12) were used.
Sequence Alignment and Phylogenetic and 
Recombination Analyses
Consensus sequences were assembled and checked 
for ambiguities by using SeqMan version 8.0.2 
(DNASTAR, Madison, WI, USA). Sequence alignments 
were generated with MEGA version 5 (14) by using the 
standard settings and manual correction. The genome 
sequence databases of reference strains H99 (culture 
collection no. CBS8710; C. neoformans variety grubii; 
AFLP1/VNI; Broad Institute [www.broadinstitute.
org/annotation/genome/cryptococcus_neoformans/]) 
and JEC21 (culture collection no. CBS10513; C. 
neoformans variety neoformans; AFLP2/VNIV; Stanford 
Genome Technology Center [www-sequence.stanford.
edu/group/C.neoformans/]) were used to extract the 
corresponding sequences for all 10 investigated nuclear 
loci to serve as an outgroup. The best fi tting nucleotide 
substitution model was determined by using MrModeltest 
version 2 (15) and was conducted for the complete C. 
gattii 10-loci MLST, for the accepted consensus MLST 
scheme (CAP59, GPD1, IGS1, LAC1, PLB1, SOD1, 
and URA5) (9), and a previously launched C. gattii 
MLST scheme (CAP10, GPD1, IGS1, LAC1, MPD1, 
PLB1, and TEF1) (12). As a result, the HKY G+I  model 
(Hasegawa-Kishino-Yano plus gamma distributed with 
invariant sites) was the best model to use for analyzing the 
phylogeny of the C. gattii isolates for all 3 datasets. The 
evolutionary history was inferred by using the maximum-
likelihood method in MEGA version 5 (14). A bootstrap 
consensus tree was inferred from 1,000 replicates to show 
the relevant lineages obtained in this analysis.
We calculated the haplotype diversity (HR), equal to 
the Simpson diversity index (D), by using the Microsoft 
Excel (Microsoft, Redmond, WA, USA) add-in called 
Haplotype Analysis (16). For this purpose, sequences were 
collapsed into sequence type numbers (online Technical 
Appendix Table 1).
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Results
AFLP Genotypes and Geographic Distribution
The 301 C. gattii isolates collected from Europe and other 
areas around the world could be divided into the following 
genotypes: 146 AFLP4/VGI (50.2%; 72 from Europe), 22 
AFLP5/VGIII (7.6%; 1 from Europe), 108 AFLP6/VGII 
(37.1%; 23 from Europe), 13 AFLP7/VGIV (4.5%; 2 from 
Europe), and 2 AFLP10/VGIV (0.7%; both from Europe). 
From 10 isolates (7 AFLP8 [5 from Europe] and 3 AFLP9 
[2 from Europe]), genotypes represented interspecies C. 
neoformans × C. gattii hybrids. These 10 isolates were 
excluded from further analysis because amplifi ed fragments 
of hybrid isolates will result in mixtures of different alleles. 
The 57 human patient isolates from Europe were obtained 
from 40 patients (online Technical Appendix Table 1). The 
genotypic diversity of the remaining 291 C. gattii isolates 
(100 from Europe, 191 from other areas) with a haploid 
genotype is shown in the Table.
Phylogeographic Origin 
Sequence type diversity was calculated for each of 
the MLST loci, all 10 loci, and the combined datasets 
according to Fraser et al. (12) and Meyer et al. (9) (online 
Technical Appendix Table 3). The CAP10 locus showed 
the lowest overall diversity (nST = 19; DST = 0.765) and 
the IGS1 locus showed the highest diversity (nST = 52; 
DST = 0.930). The 10-loci MLST dataset showed the highest 
diversity (nST = 150; DST = 0.975), followed by the MLST 
scheme of Meyer et al. (DST = 0.971) (9) and Fraser et al. 
(DST of 0.959) (12). The latter MLST scheme differentiated 
more sequence types than the consensus MLST scheme 
(nST = 136 vs. 127).
Maximum-likelihood analysis of the MLST data 
showed that the C. gattii isolates clustered in 5 monophyletic 
clusters, which were highly supported and agreed with 
the AFLP genotypes (Figure; online Technical Appendix 
Figure). When each genotypic cluster was separately 
analyzed, support values of the branches were low, <75 
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Table. Distribution of Cryptococcus gattii strains* 
Source of isolation 
Genotype
Total† Total (%) AFLP4/VGI AFLP5/VGIII AFLP6/VGII AFLP7/VGIV AFLP10/VGIV 
All C. gattii isolates 146 22 108 13 2 0 291 (100) 
 Human 84 16 68 12 2 0 182 (62.5)‡ 
 Environment 37 5 17 0 0 0 59 (20.3)‡ 
 Animal 24 0 23 1 0 0 48 (16.5)‡ 
 Unknown 1 1 0 0 0 0 2 (0.7)‡ 
Africa        
 Human 18 0 3 8 0 29 36 (12.7)§ 
 Environment 6 0 0 0 0 6 
 Animal 0 0 0 1 0 1 
Asia (clinical) 19 0 5 2 0 26 26 (8.9)§ 
Australia        
 Human 2 1 8 0 0 11 18 (6.2)§ 
 Environment 5 0 1 0 0 6 
 Animal 0 0 1 0 0 1 
Europe¶        
 Human 29# 1** 23†† 2‡‡ 2§§ 57 100 (34.4)§ 
 Environment 22 0 0 0 0 22 
 Animal 21 0 0 0 0 21 
North America¶        
 Human 3 8 19 0 0 30 69 (23.7)§ 
 Environment 4 3 10 0 0 17 
 Animal 2 0 20 0 0 22 
South America¶        
 Human 12 3 10 0 0 25 36 (12.4)§ 
 Environment 0 2 6 0 0 8 
 Animal 1 0 2 0 0 3 
Unknown        
 Human 1 3 0 0 0 4 6 (2.1)§ 
 Unknown 1 1 0 0 0 2 
*The number of C. gattii isolates is provided for each geographic area and further subdivided per genotype and source of isolation. AFLP, amplified 
fragment length polymorphism; human, human clinical patient. 
†Total number of isolates per geographic area. 
‡The percentage of isolates is given for the source of isolation subset.  
§The percentage of isolates is given as a percentage of all isolates.  
¶Ten interspecies hybrid C. gattii × C. neoformans isolates were excluded from the set of isolates from Europe (n = 7), North America (n = 1), and South 
America (n = 2).  
#Twelve patients with an autochthonous acquired infection (16 isolates) and 11 patients with an infection acquired outside Europe (13 isolates). 
 **Infection acquired outside Europe.  
††Four patients with an autochthonous infection (10 isolates) and 10 patients with an infection acquired outside Europe (13 isolates).  
‡‡Two phenotypically different isolates from an emigrant from Zambia.  
§§Two phenotypically different isolates from an emigrant from Mexico. 
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(online Technical Appendix Figure). For genotype AFLP4/
VGI isolates, bootstrap support values for nearly all 
branches were low; for the second largest group formed 
by AFLP6/VGII isolates, branches were better supported.
Phylogenetic analysis demonstrated that several 
human patient genotype AFLP4/VGI isolates from 
Europe had an autochthonous origin because they formed 
a separate cluster with environmental and animal isolates 
from the same area. A set of isolates from human patients 
on the Iberian Peninsula (CCA232, CCA242L, CCA242T, 
CCA311, CCA312, CL6148) were found to be genetically 
indistinguishable from isolates obtained from animals 
or the environment in the same area (indicated in online 
Technical Appendix Figure as the European Mediterranean 
cluster). The human patient isolates from Europe with 
genotype AFLP4/VGI, which were probably acquired 
within Europe because patients did not have histories of 
travel outside Europe, are IP2005/215 and IP2006/958 
(France), RKI85/888 (Germany), 5UM and 75UM (Italy), 
RKI97/482 (Portugal), and CBS2502 (the Netherlands). 
Some of these human patient isolates were closely related 
(e.g., IP2005/215 and RKI97/482) or even genetically 
indistinguishable (e.g., CBS2502 and RKI85/888).
A large proportion of the human patient and 
environmental isolates of C. gattii AFLP4/VGI from Italy 
and Spain formed a novel autochthonous Mediterranean 
MLST cluster that was genetically homogeneous, 
irrespective of their origin or mating type (Figure, online 
Technical Appendix Figure). C. gattii AFLP4/VGI was 
involved with numerous small outbreaks among goats in 
Spain, and the isolates were genetically indistinguishable 
from recently obtained human patient, animal, and 
environmental isolates from different provinces in Spain as 
well as from AFLP4/VGI mating-type a isolates from Italy 
(online Technical Appendix Figure).
Several C. gattii genotype AFLP6/VGII infections were 
found to have originated in Europe (e.g., the IP1998/1037–
1 and −2, IP2003/125, and CCA242 isolates), and all fell 
within a cluster that could not be linked to an environmental 
source. The same holds true for the human patient isolates 
from Greece (AV54S, –W, and IUM01–4731), which came 
from the same patient who had no history of travel outside 
Greece.
In the phylogenetic analysis, isolates from human 
patients in Europe were also observed next to those 
originating from other geographic areas. The most striking 
example was a set of 4 human patient isolates from citizens 
of Denmark, the Netherlands, Germany, and Switzerland, 
in whom cryptococcosis developed after they had visited 
Vancouver Island, British Columbia, Canada. The isolates 
obtained from these tourists (CBS10485, RKI06/496, 
RKI01/774, and CBS10866, respectively) had MLST 
profi les identical to that of C. gattii AFLP6A/VGIIa, 
the genotype that caused the Vancouver Island outbreak 
(Figure 1; online Technical Appendix Figure) (17–19). The 
outbreak-related sets of AFLP6A/VGIIa and AFLP6C/
VGIIc isolates from the Vancouver Island and Pacifi c 
Northwest outbreaks, respectively, are within outbreak-
specifi c clusters (Figure, online Technical Appendix 
Figure). A similar fi nding was observed for a set of 5 human 
patient C. gattii AFLP6B/VGIIb isolates (IP1996/1120–1 
and −2, IP1999/901–1 and −2, and IP2000/87) in France, 
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Figure. Maximum-likelihood phylogenetic analysis based on 10-
loci multilocus sequence type data of Cryptococcus gattii isolates 
(condensed). Phylogenetic relatedness of 150 STs representing the 
291 C. gattii isolates, calculated by using the maximum-likelihood 
algorithm and rooted by using the 2 C. neoformans reference 
strains CBS8710 (genotype AFLP1/VNI) and CBS10513 (genotype 
AFLP2/VNIV). Closely related sequence types were collapsed into 
1 branch shown by multiple sequence type numbers. Boldface 
indicates sequence types that are within a shaded area belong 
to a specifi ed C. gattii cluster; B, M, PNW, and VIO represent 
clusters from Brazil; Mediterranean Europe; the US Pacifi c 
Northwest outbreak; and the Vancouver Island, British Columbia, 
Canada, outbreak, respectively. AFLP, amplifi ed fragment length 
polymorphism; ST, sequence type. Scale bar indicates number 
of substitutions per site. See online Technical Appendix Figure 
(wwwnc.cdc.gov/EID/pdfs/12-0068-Techapp.pdf) for a detailed 
phylogenetic analysis.
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which had been obtained from patients who had emigrated 
from Africa to France and which were genetically 
indistinguishable from an isolate (IP2001/935–1) from a 
resident of Senegal (online Technical Appendix Figure). 
This set of 5 isolates from France and 1 from Senegal were 
closely related to isolates from the Vancouver Island and 
Pacifi c Northwest outbreaks; however, it seems unlikely 
that the patient from Senegal had traveled to these outbreak 
areas, and none of the patients in France reported having 
traveled to Canada or the United States.
A set of C. gattii AFLP4/VGI mating-type α isolates 
from Portugal (IP1997/18) and Belgium (IHEM19725B 
and –S) was found to be indistinguishable from human 
patient isolates from the Democratic Republic of the 
Congo and Rwanda (B3939 and CBS6289, which were 
both mating-type a, and IHEM10602S, IHEM10769S, and 
IHEM10769W, which were mating-type α) (Figure; online 
Technical Appendix Figure). Both phenotypically different 
isolates of IHEM19725 were obtained from an HIV-infected 
patient from Rwanda who had emigrated to Belgium. The 
CBS1622 isolate from Europe, obtained from a patient with 
the oldest documented case of a C. gattii infection (20), 
was found to be genetically indistinguishable from a set of 
isolates from North America.
The single C. gattii AFLP5/VGIII isolate from a 
24-year-old immunocompetent patient from Germany 
(isolate RKI97/310) (21) clustered with human patient 
and environmental isolates from Mexico (online Technical 
Appendix Figure). The 2 C. gattii AFLP7/VGIV isolates 
CBS7952D and CBS7952S, obtained from an HIV-infected 
patient in Sweden, were genetically indistinguishable from 
each other and had a unique MLST profi le that clustered 
with human patient isolates from Africa. According to the 
patient’s history, years before the onset of cryptococcal 
infection, she had emigrated from Zambia to Sweden 
(online Technical Appendix Figure). Another example 
of a reactivated dormant C. gattii infection is that of the 
human patient isolate from Italy, IUM92–6682 (AFLP4/
VGI), obtained from an immunocompetent immigrant from 
Brazil, which had an identical MLST profi le to 6 human 
patient mating-type α isolates (IHEM14934, IHEM14956, 
IHEM14965, IHEM14968, IHEM14976, and IHEM14984) 
from Brazil (Figure, online Technical Appendix Figure).
Infection was acquired outside Europe for 24 of these 
patients (31 isolates) and within Europe for 16 patients 
(26 isolates) (Table; online Technical Appendix Figure). 
Among these 57 human patient isolates, most (47 [82.5%]) 
were obtained since 1995, the remaining 10 (17.5%) were 
isolated during 1895–1994. One of these isolates originated 
from 1985, another 2 isolates (CBS1622 and CBS2502), 
from 1895 and 1957, were retrospectively found to 
represent C. gattii isolates from Europe (20,22).
Discussion
In Europe, C. gattii has been reported as a rare cause of 
apparently autochthonous cryptococcal infections (1). The 
earliest documented case that turned out to be caused by 
C. gattii in Europe was made by Curtis in 1896 (20). Until 
the 1980s, cryptococcosis was rarely observed in Europe 
and C. gattii infections were especially rare; only 2 cases 
have retrospectively been found (20,22). In the 1980s, 
infections were reported for 2 immunocompetent citizens 
of Germany, who had never traveled abroad (23,24). 
Subsequent case reports described C. gattii infections that 
were imported or acquired in Europe (25,26). Since 1995, 
the number of reports of C. gattii infections increased and 
describe C. gattii infections in humans and animals from 
Greece (27), Italy (28,29), and Spain (5,30–33). In the 
current study, 8 (20%) cases were observed until 1995, and 
32 (80%) cases in humans have been observed since 1995. 
We excluded cases for which an isolate was not available 
for confi rmation. This exclusion is especially relevant 
in that we re-identifi ed a reported C. gattii infection as 
actually being caused by C. neoformans (34). These data 
suggest that during the past 2 decades, C. gattii has been 
emerging in Europe.
In the current study, 16 (40%) of the human patient 
isolates from Europe were found to have an autochthonous 
origin in Europe that either could be linked to environmental 
isolates from the Mediterranean area or that came from 
patients who had never traveled outside their resident 
country. A total of 24 (60%) isolates could be linked to 
C. gattii–endemic regions in Brazil, the United States, 
Africa, and the Vancouver Island outbreak region. These 
observations demonstrate that C. gattii infections can be 
imported subclinically and can cause infections after being 
dormant for many years.
Nearly all isolates from Mediterranean Europe 
belonged to genotype AFLP4/VGI, and MLST analysis 
showed that these isolates form a separate cluster within 
this genotype (Figure; online Technical Appendix Figure) 
(5). C. gattii genotype AFLP4/VGI has also recently been 
reported from the environment in the Netherlands, but 
these isolates were not similar to any of the AFLP4/VGI 
isolates from Mediterranean Europe or to isolate CBS2502, 
which was isolated in 1957 from a pregnant citizen of the 
Netherlands, who had never traveled abroad but who died 
of cryptococcosis (4). Isolate CBS2502 is genotypically 
identical to isolate RKI85/888, which was isolated from a 
previously healthy citizen of Germany, who also had never 
traveled outside Germany. These 2 cases strongly suggest 
that different genotypes of C. gattii AFLP4/VGI occur in 
the environment of northwestern Europe because isolates 
from patients were genetically different from the recently 
reported isolates from the environment of the Netherlands 
(this study; 4).
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In conclusion, C. gattii is emerging in Europe, and 
the isolates from Europe can be divided into 5 genotypic 
clusters. Most C. gattii infections in Europe are probably 
autochthonous, and several infections are proven to 
have been acquired outside the European continent, e.g., 
during visits to C. gattii–endemic regions, such as the 
Vancouver Island outbreak area or before migration to 
Europe from C. gattii–endemic regions in Africa and South 
America. Reactivation of dormant C. gattii infections 
and of infections acquired outside Europe after immune 
suppression occurs more often than previously assumed. 
This fi nding might suggest that C. gattii infections caused 
by certain genotypes are associated with altered immune 
status of the human host. Thus, C. gattii is probably a more 
opportunistic pathogen, as has recently been hypothesized, 
than a strictly primary pathogen (18,35). C. gattii isolates 
with genotypes AFLP5/VGIII and AFLP7/VGIV were 
rarely found in Europe and were all acquired outside the 
European continent. However, these genotypes have 
frequently been isolated from HIV-infected persons and 
other immunocompromised patients in Africa and the 
American continents (1,7,36). A connection seems to exist 
between these C. gattii genotypes and the host’s immune 
status. Further epidemiologic and immunologic research is 
needed to unravel this apparent correlation.
Acknowledgments
We thank Karen Bartlett, Alf Botha, Eddy Byrnes III, Manuel 
Cuenca-Estrella, Françoise Dromer, Martine Gari-Toussaint, 
Jesús Guinea, Joseph Heitman, Connie Jarstrand, Margareth Ip, 
Greetje Kampinga, Maarten Scholing, and Marianna Viviani for 
providing Cryptococcus spp.  isolates.
 This work was conducted at the CBS-KNAW Fungal 
Biodiversity Centre in Utrecht, the Netherlands. The data are 
available online (www.cbs.knaw.nl/publications/online.aspx). 
Research performed by F.H. was fi nancially supported by the Odo 
van Vloten Foundation, the Netherlands.
Dr Hagen is a medical molecular microbiologist trainee at 
the Canisius-Wilhelmina Hospital in Nijmegen, the Netherlands. 
His research interests include medical mycology, especially the 
development of novel molecular approaches to understand the 
epidemiology of fungal pathogens. 
References
  1.  Springer DJ, Chaturvedi V. Projecting global occurrence of 
Cryptococcus gattii. Emerg Infect Dis. 2010;16:14–20. http://
dx.doi.org/10.3201/eid1601.090369
  2.  Kidd SE, Hagen F, Tscharke RL, Huynh M, Bartlett KH, Fyfe M, et 
al. A rare genotype of Cryptococcus gattii caused the cryptococcosis 
outbreak on Vancouver Island (British Columbia, Canada). Proc Natl 
Acad Sci U S A. 2004;101:17258–63. http://dx.doi.org/10.1073/
pnas.0402981101
  3.  Carriconde F, Gilgado F, Arthur I, Ellis D, Malik R, van de 
Wiele N, et al. Clonality and α-a recombination in the Australian 
Cryptococcus gattii VGII population—an emerging outbreak in 
Australia. PLoS One. 2011;6:e16936. http://dx.doi.org/10.1371/
journal.pone.0016936
  4.  Chowdhary A, Randhawa HS, Boekhout T, Hagen F, Klaassen 
CHW, Meis JF. Temperate climate niche for Cryptococcus gattii in 
northern Europe. Emerg Infect Dis. 2012;18:172–4. http://dx.doi.
org/10.3201/eid1801.111190
  5.  Colom MF, Hagen F, Gonzalez A, Mellado A, Morera N, Linares C, 
et al. Ceratonia siliqua (carob) trees as natural habitat and source of 
infection by Cryptococcus gattii in the Mediterranean environment. 
Med Mycol. 2012;50:67–73.
  6.  Boekhout T, Theelen B, Diaz M, Fell JW, Hop WC, Abeln EC, et al. 
Hybrid genotypes in the pathogenic yeast Cryptococcus neoformans. 
Microbiology. 2001;147:891–907.
  7.  Bovers M, Hagen F, Boekhout T. Diversity of the Cryptococcus 
neoformans–Cryptococcus gattii species complex. Rev Iberoam 
Micol. 2008;25:S4–12. http://dx.doi.org/10.1016/S1130-1406(08)
70019-6
  8.  Hagen F, Illnait-Zaragozi MT, Bartlett KH, Swinne D, Geertsen E, 
Klaassen CH, et al. In vitro antifungal susceptibilities and amplifi ed 
fragment length polymorphism genotyping of a worldwide collection 
of 350 clinical, veterinary, and environmental Cryptococcus gattii 
isolates. Antimicrob Agents Chemother. 2010;54:5139–45. http://
dx.doi.org/10.1128/AAC.00746-10
  9.  Meyer W, Aanensen DM, Boekhout T, Cogliati M, Diaz MR, 
Esposto MC, et al. Consensus multi-locus sequence typing scheme 
for Cryptococcus neoformans and Cryptococcus gattii. Med Mycol. 
2009;47:561–70. http://dx.doi.org/10.1080/13693780902953886
10.  Simwami SP, Khayhan K, Henk DA, Aanensen DM, Boekhout T, 
Hagen F, et al. Low diversity Cryptococcus neoformans variety 
grubii multilocus sequence types from Thailand are consistent with 
an ancestral African origin. PLoS Pathog. 2011;7:e1001343. http://
dx.doi.org/10.1371/journal.ppat.1001343
11.  Byrnes EJ III, Li W, Lewit Y, Ma H, Voelz K, Ren P, et al. Emergence 
and pathogenicity of highly virulent Cryptococcus gattii genotypes 
in the northwest United States. PLoS Pathog. 2010;6:e1000850. 
http://dx.doi.org/10.1371/journal.ppat.1000850
12.  Fraser JA, Giles SS, Wenink EC, Geunes-Boyer SG, Wright JR, 
Diezmann S, et al. Same-sex mating and the origin of the Vancouver 
Island Cryptococcus gattii outbreak. Nature. 2005;437:1360–4. 
http://dx.doi.org/10.1038/nature04220
13.  Bovers M, Hagen F, Kuramae EE, Boekhout T. Six monophyletic 
lineages identifi ed within Cryptococcus neoformans and 
Cryptococcus gattii by multi-locus sequence typing. Fungal Genet 
Biol. 2008;45:400–21. http://dx.doi.org/10.1016/j.fgb.2007.12.004
14.  Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar 
S. MEGA5: Molecular Evolutionary Genetics Analysis using 
maximum likelihood, evolutionary distance, and maximum 
parsimony methods. Mol Biol Evol. 2011;28:2731–9. http://dx.doi.
org/10.1093/molbev/msr121
15.  Nylander JAA. MrModeltest v.2. Uppsala: Evolutionary Biology 
Centre, Uppsala University: 2004 [cited 2012 Aug 9]. http://www.
abc.se/~nylander/
16.  Eliades N-G, Eliades DG. Haplotype Analysis: software for analysis 
of haplotype data. Forest Goettingen (Germany): Genetics and 
Forest Tree Breeding, Georg-August University Goettingen,. 2009 
[cited 2012 Aug 9]. http://www.uni-goettingen.de/en/134935.html
17.  Georgi A, Schneemann M, Tintelnot K, Calligaris-Maibach RC, 
Meyer S, Weber R, et al. Cryptococcus gattii meningoencephalitis 
in an immunocompetent person 13 months after exposure. Infection. 
2009;37:370–3. http://dx.doi.org/10.1007/s15010-008-8211-z
 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 18, No. 10, October 2012 1623
RESEARCH
18.  Hagen F, van Assen S, Luijckx GJ, Boekhout T, Kampinga GA. 
Activated dormant Cryptococcus gattii infection in a Dutch 
tourist who visited Vancouver Island (Canada): a molecular 
epidemiological approach. Med Mycol. 2010;48:528–31. http://
dx.doi.org/10.3109/13693780903300319
19.  Lindberg J, Hagen F, Laursen A, Stenderup J, Boekhout T. 
Cryptococcus gattii risk for tourists visiting Vancouver Island, 
Canada. Emerg Infect Dis. 2007;13:178–9. http://dx.doi.
org/10.3201/eid1301.060945
20.  Curtis F. Contribution a l’étude de la saccharomycose humaine. Ann 
Inst Pasteur (Paris). 1896;10:449–68.
21.  Grosse P, Tintelnot K, Söllner O, Schmitz B. Encephalomyelitis 
due to Cryptococcus neoformans var. gattii presenting as spinal 
tumour: case report and review of the literature. J Neurol Neurosurg 
Psychiatry. 2001;70:113–6. http://dx.doi.org/10.1136/jnnp.70.1.113
22.  Janssens J, Beetstra A. Torulosis in a pregnant female, with 
localization in the lungs [in Dutch]. Ned Tijdschr Geneeskd. 
1957;101:824–6.
23.  Kohl KH, Hof H, Schrettenbrunner A, Seeliger HP, Kwon-Chung 
KJ. Cryptococcus neoformans var. gattii in Europe. Lancet. 
1985;325:1515. http://dx.doi.org/10.1016/S0140-6736(85)92300-1
24.  Schaberg T, Mai J, Thalmann U, Seibold M, Staib F. Cryptococcoma 
of the lung—a contribution to diagnosis and therapy [in German]. 
Internist (Berl). 1988;29:510–5.
25.  Dromer F, Ronin O, Dupont B. Isolation of Cryptococcus neoformans 
var. gattii from an Asian patient in France: evidence for dormant 
infection in healthy subjects. J Med Vet Mycol. 1992;30:395–7. 
http://dx.doi.org/10.1080/02681219280000511
26.  Dromer F, Mathoulin S, Dupont B, Laporte A. Epidemiology of 
cryptococcosis in France: a 9-year survey (1985–1993). French 
Cryptococcosis Study Group. Clin Infect Dis. 1996;23:82–90. http://
dx.doi.org/10.1093/clinids/23.1.82
27.  Velegraki A, Kiosses VG, Pitsouni H, Toukas D, Daniilidis VD, 
Legakis NJ. First report of Cryptococcus neoformans var. gattii 
serotype B from Greece. Med Mycol. 2001;39:419–22.
28.  Iatta R, Hagen F, Fico C, Lopatriello N, Boekhout T, Montagna MT. 
Cryptococcus gattii infection in an immunocompetent patient from 
southern Italy. Mycopathologia. 2012 ;174:87–92.
29.  Montagna MT, Viviani MA, Pulito A, Aralla C, Tortorano AM, 
Fiore L, et al. Cryptococcus neoformans var. gattii in Italy. Note 
II. Environmental investigation related to an autochthonous clinical 
case in Apulia. J Mycol Med. 1997;7:93–6.
 30.  Baró T, Torres-Rodríguez JM, De Mendoza MH, Morera Y, Alía 
C. First identifi cation of autochthonous Cryptococcus neoformans 
var. gattii isloated from goats with predominantly severe pulmonary 
disease in Spain. J Clin Microbiol. 1998;36:458–61.
31.  Colom MF, Frasés S, Ferrer C, Jover A, Andreu M, Reus S, et al. 
First case of human cryptococcosis due to Cryptococcus neoformans 
var. gattii in Spain. J Clin Microbiol. 2005;43:3548–50. http://
dx.doi.org/10.1128/JCM.43.7.3548-3550.2005
32.  Guinea J, Hagen F, Peláez T, Boekhout T, Tahoune H, Torres-
Narbona M, et al. Antifungal susceptibility, serotyping, and 
genotyping of clinical Cryptococcus neoformans isolates collected 
during 18 years in a single institution in Madrid, Spain. Med Mycol. 
2010;48:942–8. http://dx.doi.org/10.3109/13693781003690067
33.  Solla I, Morano LE, Vasallo F, Cuenca-Estrella M. Cryptococcus 
gattii meningitis: observation in a Spanish patient [in Spanish]. 
Enferm Infecc Microbiol Clin. 2008;26:395–6. http://dx.doi.
org/10.1157/13123846
34.  Bodasing N, Seaton RA, Shankland GS, Kennedy D. Cryptococcus 
neoformans var. gattii meningitis in an HIV-positive patient: fi rst 
observation in the United Kingdom. J Infect. 2004;49:253–5. http://
dx.doi.org/10.1016/j.jinf.2003.06.001
35.  MacDougall L, Fyfe M, Romney M, Starr M, Galanis E. Risk factors 
for Cryptococcus gattii infection, British Columbia, Canada. Emerg 
Infect Dis. 2011;17:193–9.
36.  Litvintseva AP, Thakur R, Reller LB, Mitchell TG. Prevalence of 
clinical isolates of Cryptococcus gattii serotype C among patients 
with AIDS in sub-Saharan Africa. J Infect Dis. 2005;192:888–92. 
http://dx.doi.org/10.1086/432486
Address for correspondence: Ferry Hagen, Canisius-Wilhelmina Hospital, 
Department of Medical Microbiology and Infectious Diseases, Weg door 
Jonkerbos 100, NL-6532 SZ Nijmegen, the Netherlands; email: f.hagen@
gmail.com
1624 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 18, No. 10, October 2012
